Aosuwei Omeprazole and Sodium Bicarbonate for Suspension (I)

1. Indications and Usage
Active Duodenal Ulcer: Short-term treatment of active duodenal ulcer, with most patients healing within 4 weeks.
Gastroesophageal Reflux Disease (GERD): Treatment of GERD symptoms, including heartburn.
Erosive Esophagitis: Short-term treatment (4-8 weeks) of erosive esophagitis resulting from GERD, and maintenance of healed erosive esophagitis.
2. Dosage and Administration
Recommended Dose: 20 mg once daily for the treatment of active duodenal ulcer, GERD symptoms, or maintenance of healed erosive esophagitis.
Administration: For oral administration, mix the entire contents of the packet with 5-10 mL of water in a small cup. Stir immediately and consume. Do not mix with liquids or food other than water.
Timing: Administer at least 1 hour before meals on an empty stomach.
Nasogastric/Oral Gavage: Mix with 20 mL of water in a syringe with a catheter, shake to dissolve, and administer immediately. Flush the tube with an equal amount of water afterward.
3. Mechanism of Action
Omeprazole: A proton pump inhibitor that specifically inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, effectively suppressing gastric acid secretion.
Sodium Bicarbonate: An immediate-acting antacid that neutralizes existing gastric acid. In this formulation, it also provides local alkalization to protect omeprazole from acid degradation, allowing for faster onset of action.
4. Safety and Warnings
Hypersensitivity: Contraindicated in patients with known hypersensitivity to benzimidazoles or any component of the formulation.
Rilpivirine Interaction: Contraindicated in patients receiving products containing rilpivirine, as co-administration may lead to loss of virologic response.
Long-Term Risks: Prolonged use may be associated with an increased risk of bone fracture, hypomagnesemia, and vitamin B12 deficiency.
Infection Risk: Increased risk of gastrointestinal infections, including Clostridium difficile-associated diarrhea.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Common reactions include abdominal pain, nausea, diarrhea, and headache. Rare but serious reactions include severe skin reactions (e.g., Stevens-Johnson syndrome), acute interstitial nephritis, and hepatic dysfunction.
Clinical Research: Clinical trials have demonstrated that this formulation significantly improves the speed of symptom relief for GERD-related heartburn compared to standard omeprazole formulations, with efficacy comparable to established reference drugs.
6. Drug Interactions
Atazanavir and Nelfinavir: Co-administration may significantly decrease plasma concentrations of these protease inhibitors and is not recommended.
Methotrexate: Proton pump inhibitors may decrease the clearance of methotrexate, potentially increasing toxicity; caution is advised.
Warfarin: Long-term use may occasionally affect International Normalized Ratio (INR) and prothromrin time, requiring monitoring.
7. Pharmaceutical Information
Composition: Each packet contains 20 mg of Omeprazole and 1680 mg of Sodium Bicarbonate.
Appearance: White or off-white powder.
Storage: Store in a well-closed container at controlled room temperature (below 25°C) in a dry place.